SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Thursday reported a loss of $4.7 million in its first quarter.
On a per-share basis, the San Diego-based company said it had a loss of 14 cents.
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 12 cents per share.
The biotechnology company posted revenue of $7 million in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $8.3 million.
In the final minutes of trading on Thursday, the company's shares hit 84 cents. A year ago, they were trading at $3.68.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CNAT at https://www.zacks.com/ap/CNAT